(R)-ethyl 2-(1-(2,4-dimethoxybenzyl)-3-oxopiperazin-2-yl)acetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-ethyl 2-(1-(2,4-dimethoxybenzyl)-3-oxopiperazin-2-yl)acetate
• 英文别名: ethyl 2-[(2R)-1-[(2,4-dimethoxyphenyl)methyl]-3-oxopiperazin-2-yl]acetate
• 化学式: C₁₇H₂₄N₂O₅
• 分子量: 336.388
• InChiKey: ILYQCDYWLJHIMH-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  77.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-ethyl 2-(1-(2,4-dimethoxybenzyl)-3-oxopiperazin-2-yl)acetate 在 sodium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 40.75h， 生成 ethyl 2-(7-(2,4-dimethoxybenzyl)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6,7,8-tetrahydro-[1,2,4] triazolo [4,3-a]pyrazin-8-yl)acetate
  参考文献：
  名称：

  Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)

  摘要：

  Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE > 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.

  DOI：

  10.1021/acsmedchemlett.5b00117

文献信息

• Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)
  作者：Hamid R. Hoveyda、Graeme L. Fraser、Guillaume Dutheuil、Mohamed El Bousmaqui、Julien Korac、François Lenoir、Alexey Lapin、Sophie Noël

  DOI：10.1021/acsmedchemlett.5b00117

  日期：2015.7.9

  Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE > 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.